心血管药物研发：一家研发型制药公司的视角
Cardiovascular drug discovery: a perspective from a research-based pharmaceutical company.
作者信息
Gromo G, Mann J, Fitzgerald J D
机构信息
F. Hoffmann-La Roche AG, CH-4070 Basel, Switzerland.
Translational Medicine, Cardiovascular and Metabolism, F. Hoffmann-La Roche AG, CH-4070 Basel, Switzerland.
出版信息
Cold Spring Harb Perspect Med. 2014 Jun 2;4(6):a014092. doi: 10.1101/cshperspect.a014092.
Abstract
The theme of this review is to summarize the evolving processes in cardiovascular drug discovery and development within a large pharmaceutical company. Emphasis is placed on the contrast between the academic and industrial research operating environments, which can influence the effectiveness of research collaboration between the two constituencies, but which plays such an important role in drug innovation. The strategic challenges that research directors face are also emphasized. The need for improved therapy in many cardiovascular indications remains high, but the feasibility in making progress, despite the advances in molecular biology and genomics, is also assessed.
摘要
本综述的主题是总结一家大型制药公司心血管药物研发的演变过程。重点在于学术研究与产业研究运营环境之间的对比，这两者会影响两个群体间研究合作的成效，但在药物创新中却起着至关重要的作用。同时也强调了研究主管所面临的战略挑战。尽管分子生物学和基因组学取得了进展，但许多心血管适应症对改进治疗的需求仍然很高，本文也评估了取得进展的可行性。
相似文献
1
Cardiovascular drug discovery: a perspective from a research-based pharmaceutical company.心血管药物研发：一家研发型制药公司的视角
Cold Spring Harb Perspect Med. 2014 Jun 2;4(6):a014092. doi: 10.1101/cshperspect.a014092.
2
Future pharmaceutical research: the need to look beyond science.未来的药物研究：超越科学的必要性。
Future Med Chem. 2014 May;6(7):721-3. doi: 10.4155/fmc.14.36.
3
The Current Status of Drug Discovery and Development as Originated in United States Academia: The Influence of Industrial and Academic Collaboration on Drug Discovery and Development.美国学术界药物发现与开发的现状：工业界与学术界合作对药物发现与开发的影响。
Clin Transl Sci. 2018 Nov;11(6):597-606. doi: 10.1111/cts.12577. Epub 2018 Jul 30.
4
Vertical disintegration: a strategy for pharmaceutical businesses in 2009?纵向解体：2009年制药企业的一项战略？
Nat Rev Drug Discov. 2009 Jun;8(6):435. doi: 10.1038/nrd2914.
5
Developability assessment in pharmaceutical industry: An integrated group approach for selecting developable candidates.制药行业中的可开发性评估：一种用于选择可开发候选物的综合分组方法。
J Pharm Sci. 2009 Jun;98(6):1962-79. doi: 10.1002/jps.21592.
6
Q&A: Bernard Munos.问答：伯纳德·穆诺斯
Nature. 2016 May 12;533(7602):S59. doi: 10.1038/533S59a.
7
An open source pharma roadmap.一份开源制药路线图。
PLoS Med. 2017 Apr 18;14(4):e1002276. doi: 10.1371/journal.pmed.1002276. eCollection 2017 Apr.
8
Ask the experts: the challenges and benefits of flow chemistry to optimize drug development.专家问答：流动化学在药物开发中的挑战与优势
Future Med Chem. 2012 Sep;4(14):1779-89. doi: 10.4155/fmc.12.106.
9
Competition: Unlikely partnerships.竞争：不太可能的伙伴关系。
Nature. 2016 May 12;533(7602):S56-8. doi: 10.1038/533S56a.
10
Academic drug discovery: current status and prospects.学术性药物研发：现状与前景
Expert Opin Drug Discov. 2015;10(9):937-44. doi: 10.1517/17460441.2015.1059816. Epub 2015 Jun 19.
引用本文的文献
1
New Perspectives in Cardiac and Vascular Diseases.心脏与血管疾病的新视角
Biomedicines. 2025 Jun 4;13(6):1377. doi: 10.3390/biomedicines13061377.
2
Biomimetic Approaches in the Development of Optimised 3D Culture Environments for Drug Discovery in Cardiac Disease.用于心脏病药物研发的优化3D培养环境开发中的仿生方法
Biomimetics (Basel). 2025 Mar 26;10(4):204. doi: 10.3390/biomimetics10040204.
3
FRESH™ 3D bioprinted cardiac tissue, a bioengineered platform for pharmacology.FRESH™ 3D生物打印心脏组织，一种用于药理学的生物工程平台。
APL Bioeng. 2023 Dec 1;7(4):046113. doi: 10.1063/5.0163363. eCollection 2023 Dec.
4
Human iPSCs and Genome Editing Technologies for Precision Cardiovascular Tissue Engineering.用于精准心血管组织工程的人类诱导多能干细胞和基因组编辑技术
Front Cell Dev Biol. 2021 Jun 28;9:639699. doi: 10.3389/fcell.2021.639699. eCollection 2021.
5
Human iPSC modeling of heart disease for drug development.人类诱导多能干细胞在心脏病药物研发中的应用模型。
Cell Chem Biol. 2021 Mar 18;28(3):271-282. doi: 10.1016/j.chembiol.2021.02.016.
6
Intensive care for human hearts in pluripotent stem cell models.多能干细胞模型中人类心脏的重症监护
NPJ Regen Med. 2020 Mar 6;5:4. doi: 10.1038/s41536-020-0090-7. eCollection 2020.
7
Applications for Induced Pluripotent Stem Cells in Disease Modelling and Drug Development for Heart Diseases.诱导多能干细胞在心脏病疾病建模和药物开发中的应用
Eur Cardiol. 2020 Feb 26;15:1-10. doi: 10.15420/ecr.2019.03. eCollection 2020 Feb.
8
MAP4K4 Inhibition Promotes Survival of Human Stem Cell-Derived Cardiomyocytes and Reduces Infarct Size In Vivo.MAP4K4 抑制促进人源干细胞衍生心肌细胞的存活并减少体内梗死面积。
Cell Stem Cell. 2019 Apr 4;24(4):579-591.e12. doi: 10.1016/j.stem.2019.01.013. Epub 2019 Mar 7.
9
3D printed micro-scale force gauge arrays to improve human cardiac tissue maturation and enable high throughput drug testing.3D 打印微尺度力传感器阵列以改善人心肌组织成熟度并实现高通量药物测试。
Acta Biomater. 2019 Sep 1;95:319-327. doi: 10.1016/j.actbio.2018.12.026. Epub 2018 Dec 19.
10
Emerging trends in multiscale modeling of vascular pathophysiology: Organ-on-a-chip and 3D printing.血管病理生理学多尺度建模的新兴趋势：芯片器官和 3D 打印。
Biomaterials. 2019 Mar;196:2-17. doi: 10.1016/j.biomaterials.2018.07.029. Epub 2018 Jul 23.
本文引用的文献
1
The role of BRAF V600 mutation in melanoma.BRAF V600 突变在黑色素瘤中的作用。
J Transl Med. 2012 Jul 9;10:85. doi: 10.1186/1479-5876-10-85.
2
Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies.白细胞介素-6 受体通路与冠心病：82 项研究的荟萃分析协作组
Lancet. 2012 Mar 31;379(9822):1205-13. doi: 10.1016/S0140-6736(11)61931-4. Epub 2012 Mar 14.
3
Clinical utility of pharmacogenetic biomarkers in cardiovascular therapeutics: a challenge for clinical implementation.临床药理学基因组生物标志物在心血管治疗中的应用：临床实施的挑战。
Pharmacogenomics. 2012 Mar;13(4):465-75. doi: 10.2217/pgs.12.2.
4
Market watch: industry perspectives on personalized medicine.
Nat Rev Drug Discov. 2012 Mar 1;11(3):178. doi: 10.1038/nrd3677.
5
Cardiac safety, drug-induced QT prolongation and torsade de pointes (TdP).心脏安全性、药物诱导的QT间期延长和尖端扭转型室速（TdP）。
Br J Clin Pharmacol. 2012 Mar;73(3):331-4. doi: 10.1111/j.1365-2125.2012.04193.x.
6
Ignoratio elenchi: myocardial conditioning and reperfusion 'injury'.对反驳论点的无知：心肌预处理与再灌注“损伤”
Coron Artery Dis. 2012 Mar;23(2):133-6. doi: 10.1097/MCA.0b013e328350a9b8.
7
A tale of coronary artery disease and myocardial infarction.一则关于冠状动脉疾病和心肌梗死的故事。
N Engl J Med. 2012 Jan 5;366(1):54-63. doi: 10.1056/NEJMra1112570.
8
Biomarker classifiers for identifying susceptible subpopulations for treatment decisions.用于识别治疗决策中易感亚人群的生物标志物分类器。
Pharmacogenomics. 2012 Jan;13(2):147-57. doi: 10.2217/pgs.11.139. Epub 2011 Dec 21.
9
3Rs of animal testing for regenerative medicine products.动物试验再生医学产品的 3R 原则。
Sci Transl Med. 2011 Dec 7;3(112):112fs11. doi: 10.1126/scitranslmed.3003394.
10
Ischemia and reperfusion--from mechanism to translation.缺血与再灌注：从机制到转化。
Nat Med. 2011 Nov 7;17(11):1391-401. doi: 10.1038/nm.2507.
Zotero 插件